A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Oral QPX7831 in Healthy Adult Subjects
Latest Information Update: 05 Apr 2023
At a glance
- Drugs QPX 7831 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Qpex Biopharma
- 24 Mar 2023 According to Brii Biosciences media release, interim data from this study were presented at the IDWeek in October 2022.
- 22 Sep 2022 Status changed from recruiting to completed.
- 23 Aug 2022 According to Brii Biosciences media release, this trial is on track to be completed.